Trial · NCT07486934
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 5 Times Sit-To-Stand (5×STS) Time | Baseline, Week 49 | |
| Secondary | Video Hand Opening Time (vHOT) [Middle Finger] | Baseline, Week 49 | |
| Secondary | Quantitative Muscle Testing (QMT) Total | Baseline, Week 49 | |
| Secondary | Clinician Global Impression of Change (CGI-C) | Week 49 | |
| Secondary | 10-Meter Walk/Run Test (10-MWRT) Velocity (m/s) | Baseline, Week 49 | |
| Secondary | Patient Global Impression of Change (PGI-C) | Week 49 | |
| Secondary | DM1-ACTIV^C Total Score | Baseline, Week 49 | |
| Secondary | Myotonic Dystrophy Health Index (MDHI) Total | Baseline, Week 49 | |
| Secondary | Patient Global Impression of Severity (PGI-S) | Baseline, Week 49 | |
| Secondary | Clinician Global Impression of Severity (CGI-S) | Baseline, Week 49 | |
| Secondary | 9-Hole Peg Test (9-HPT) Time | Baseline, Week 49 | |
| Secondary | Myotonic Dystrophy Health Index (MDHI) Subscale Scores | Baseline, Week 49 | |
| Secondary | Maximum Observed Plasma Drug Concentration (Cmax) of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 | |
| Secondary | Time to Maximum Concentration (tmax) of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 | |
| Secondary | Area Under the Concentration-Time Curve (AUC) from Hour 0 to the Last Measurable Concentration (AUC0-tlast) of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 | |
| Secondary | Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-∞) of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 | |
| Secondary | Apparent Terminal Elimination Rate Constant (λZ) of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 | |
| Secondary | Apparent Terminal Elimination Half-Life (t½) of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 | |
| Secondary | Plasma clearance (CL) of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 | |
| Secondary | Volume of Distribution at the Terminal Phase (Vz), if Appropriate of DYNE-101 | Pre-dose, and at multiple time points up to Week 73 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07486934/registered